Ozmosi | Flublok Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Flublok

Alternative Names: Flublok
Clinical Status: Active
Latest Update: 2025-10-01
Latest Update Note: News Article

Product Description

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Intramuscular

FDA Designation: Fast Track - COVID-19 *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Brazil | Hong Kong | Mexico | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Flublok

Countries in Clinic: Czech Republic, Poland, Singapore, Spain, United States

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Influenza, Human

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
VAP00027

P3

Completed

Influenza, Human

2023-10-27

2024-05-31

Patient Enrollment|Primary Endpoints|Treatments
VAV00018

P1

Completed

Influenza, Human

2023-02-17

2023-11-08

Primary Endpoints
NCT05479370

P3

Completed

Influenza, Human

2023-04-14

11%

2024-10-16

Recent News Events

Date

Type

Title

10/01/2025

News Article

 Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

10/16/2024

News Article

 FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals

07/10/2024

News Article

 Sanofi ships U.S. influenza vaccines for the 2024/25 season

03/07/2024

PubMed

 Flublok Quadrivalent Vaccine Adjuvanted with R-DOTAP Elicits a Robust and Multifunctional CD4 T Cell Response That Is of Greater Magnitude and Functional Diversity Than Conventional Adjuvant Systems.

12/21/2023

PubMed

 Whole Blood Reactivity to Viral and Bacterial Pathogens after Non-Emergent Cardiac Surgery during the Acute and Convalescence Periods Demonstrates a Distinctive Profile of Cytokines Production Compared to the Preoperative Baseline in Cohort of 108 Patients, Suggesting Immunological Reprogramming during the 28 Days Traditionally Recognized as the Post-Surgical Recovery Period.

12/14/2023

PubMed

 Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age.

09/13/2023

News Article

 FFF Enterprises Inc. Adds COVID-19 Vaccines and Respiratory Syncytial Virus (RSV) Products to Its Comprehensive, Expanding Portfolio

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions